News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trine Pharmaceuticals, Inc. Initiates Phase 2b Trial For D-IBS


10/30/2006 8:44:06 AM

SAN FRANCISCO, Oct. 30 /PRNewswire/ -- Napo Pharmaceuticals, Inc., , which focuses on bringing proprietary products to the global marketplace in collaboration with local partners, is pleased to announce today that Trine Pharmaceuticals, Inc. ("Trine") (Waltham, Mass, USA), has initiated enrollment in a Phase 2b study evaluating the efficacy and safety of Napo's lead product candidate, crofelemer, a natural product sustainably harvested from the rain forest, for the treatment of female patients suffering from diarrhea-predominant irritable bowel syndrome (D-IBS). Trine has worldwide development and commercialization rights to crofelemer for the IBS indication. Within thirty (30) days following the initiation of this study, Trine will pay Napo a milestone payment of USD $1 million.

This multi-center, randomized, double-blind, placebo-controlled study is expected to enroll approximately 240 women in the U.S. who have D-IBS. The primary endpoint of this study will be the improvement of abdominal pain associated with D-IBS.

Commenting on this announcement, Ms Lisa Conte, Chief Executive Officer of Napo Pharmaceuticals Inc, said: "We are delighted to have announced the initiation of this key Phase 2b study in diarrhea-predominant irritable bowel syndrome (D-IBS), for which we will receive a $1 million milestone payment from our partner, Trine. With the activity observed in the phase 2a study and the risk mitigation provided by leveraging an extensive safety database of over 1,500 patients involved in clinical testing of crofelemer across four indications, we have high expectations for this new trial."

About IBS

IBS is characterized by a constellation of gastro intestinal symptoms, including diarrhea, constipation (or alternation of the two), urgency and abdominal pain. IBS may affect up to 20 percent of the population in the U.S. (estimates range from 15-20 percent; of whom 70 percent are women). More than 60 percent of the affected patients are managing either diarrhea predominant IBS or alternation IBS. It ranks second only to the common cold as a cause of lost work time in the U.S. In addition, the disease accounts for approximately 3 million physician visits in the U.S. each year, costing the U.S. economy an estimated USD $30 billion annually. The global market could be over USD $15 billion for a safe and effective D-IBS product. The market for D-IBS is largely unserved due to serious toxicities associated with black-box restrictions of GlaxoSmithKline's Lotronex, approved for the treatment of D-IBS in women.

About Napo

Napo Pharmaceuticals, Inc., focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001 and is based in California, USA, with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program:

* CRO-HIV for AIDS diarrhea, Phase 3 * CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2 * CRO-ID for acute infectious diarrhea (including cholera), Phase 2 * CRO-PED for paediatric diarrhea, Phase 1 For more information please contact: The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to develop a preclinical product, NP-500, for the treatment of insulin-resistant diseases of Type II diabetes and Syndrome X. Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions and Napo has entered its first screening relationship associated with this collection. Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.

Napo has partnerships with Trine Pharmaceuticals, Inc., of the United States of America; Glenmark Pharmaceuticals Limited of India; and AsiaPharm Group Ltd. of China. For more information please visit www.napopharma.com .

Napo Pharmaceuticals, Inc Lisa Conte, Chief Executive Officer + 650 616 1902 Charles Thompson, Chief Financial Officer + 650 616 1903 Noonan Russo David Schull + 858 546 4810 Buchanan Communications Tim Anderson, Mary-Jane Johnson 020 7466 5000 Nomura Code Securities Limited Juliet Thompson 0207 776 1204

Disclaimer: The Shares referenced in this announcement are not for distribution, directly or indirectly, in or into the United States or to any US person as defined in Regulation S under the US Securities Act of 1933, as amended ("Regulation S"). This announcement is not an offer of securities for sale into the United States or elsewhere. The Shares described above have not been registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S) unless they are registered under the Securities Act or they are exempt from registration under the Securities Act. No offer or sale of Regulation S securities has been made or will be made in the United States. Hedging transactions involving these securities may not be conducted unless in compliance with the Securities Act.

Napo Pharmaceuticals, Inc.

CONTACT: Lisa Conte, Chief Executive Officer, +1-650-616-1902, or CharlesThompson, Chief Financial Officer, +1-650-616-1903, both of NapoPharmaceuticals, Inc.; or David Schull of Noonan Russo, +1-858-546-4810; orTim Anderson or Mary-Jane Johnson, +020-7466-5000, both of BuchananCommunications; or Juliet Thompson of Nomura Code Securities Limited,+0207-776-1204, all for Napo Pharmaceuticals, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES